Recent Trends of Lung Cancer in Korea

Lee, Jae Guk; Kim, Ho Cheol; Choi, Chang‐Min

doi:10.4046/trd.2020.0134

Cited by 43 publications

(41 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Early stage non-small cell lung cancer (NSCLC) accounts for approximately 40% of all NSCLC stages ( 1 ). With the development of low-dose computed tomography (CT) and widespread application of lung cancer screening, staging shifts have increased detection of early stage lung cancers ( 2 ).…”

Section: Introductionmentioning

confidence: 99%

Prognosis and recurrence patterns in patients with early stage lung cancer: a multi-state model approach

Jeong¹,

Choi²,

Chae³

et al. 2022

Transl Lung Cancer Res

View full text Add to dashboard Cite

Background: We aimed to assess whether recurrence patterns affect survival and to use a multi-state model to predict the prognosis of early stage non-small cell lung cancer in patients who underwent surgical resection.Methods: Patients with early stage non-small cell lung cancer who underwent surgical resection at two tertiary medical centers between 2010 and 2015 were retrospectively analyzed. A multi-state model was employed with one initial state (surgery), two intermediate states (locoregional recurrence, distant metastasis), and one absorbing state (death), comprising five transitions: surgery to locoregional recurrence, surgery to distant metastasis, surgery to death without recurrence, locoregional recurrence to death, and distant metastasis to death. Cox proportional hazards models stratified for these transitions were performed with the risk factors; transition probabilities for each patient were predicted.Results: A total of 949 patients were identified [median age: 67 years, male: 614 (64.6%)]. Recurrence occurred in 194 (20.4%) patients (locoregional recurrence: 7.3%, distant metastasis: 13.1%). Hazard ratios for distant metastasis after surgery were higher for older age (hazard ratio: 1.03, 95% confidence interval:1.01-1.06) and adenocarcinoma (hazard ratio: 1.67, 95% confidence interval: 1.06-2.61). Lower lobe location exhibited a higher hazard ratio for death after surgery without recurrence (hazard ratio: 1.59, 95% confidence interval: 1.00-2.53). Stage IIB lung cancer showed a higher probability of transition to distant metastasis after surgery than other stages. Cumulative transition hazards rapidly increased in both recurrence patterns until approximately two years after surgery (locoregional recurrence: 0.052; distant metastasis: 0.104).Patients with distant metastasis were more likely to die within 5 years of surgery than those with locoregional recurrence (6.8% and 2.6%, respectively).Conclusions: With the multi-state model, risk factors and post-relapse survival probabilities differed between locoregional recurrence and distant metastasis. These findings may enable clinicians to establish personalized follow-up strategies for patients undergoing curative resection for early stage non-small cell lung cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

Prognosis and recurrence patterns in patients with early stage lung cancer: a multi-state model approach

Jeong¹,

Choi²,

Chae³

et al. 2022

Transl Lung Cancer Res

View full text Add to dashboard Cite

show abstract

“…Patients were excluded if they had undergone surgical resection, did not have a histological diagnosis, were transferred to another hospital or dropped out immediately after the diagnosis. We also excluded patients who harbored target mutations, such as epidermal growth factor receptor mutation and anaplastic lymphoma kinase rearrangement, and consequently received targeted therapies since they have a much better prognosis [20].…”

Section: Study Populationmentioning

confidence: 99%

Impact of COPD treatment on survival in patients with advanced non-small cell lung cancer

Park

Kim

et al. 2021

Preprint

View full text Add to dashboard Cite

Background Chronic obstructive pulmonary disease (COPD) is associated with a poor prognosis in patients with non-small cell lung cancer (NSCLC). However, the impact of COPD treatment on the survival of patients with advanced NSCLC remains uncertain. Methods We retrospectively investigated COPD patients among patients newly diagnosed with advanced NSCLC between September 2005 and August 2019 at a university hospital. The diagnosis of COPD was made by forced expiratory volume in 1 second (FEV1)/forced vital capacity < 0.7 with spirometry performed within one year before and after the diagnosis of NSCLC. The clinical characteristics, lung function, and survival outcomes were analyzed and compared between patients who did and did not receive COPD treatment. Results Among 221 patients with advanced NSCLC and COPD, 124 received treatment for COPD and 97 did not receive treatment for COPD. A total of 190 (86.0%) patients were newly diagnosed with COPD at the time of diagnosis of advanced NSCLC. FEV1 and FEV1 % predicted values were greater in the no-treatment group than in the COPD treatment group (P < 0.001). The median overall survival (OS) of the treatment group was 10.7 months while that of the no-treatment group was 8.7 months (P = 0.007). In multivariate Cox regression analysis, COPD treatment was independently associated with improved OS after adjustment for sex, age, body mass index, FEV1, lung cancer stage, and chemotherapy (hazard ratio, 0.71; 95% confidence interval, 0.53–0.95; P = 0.021). Conclusion COPD treatment was associated with improved OS in patients with advanced NSCLC and COPD. Therefore, pretreatment spirometry and maximal treatment for COPD may offer a chance of optimal management for patients with advanced NSCLC.

show abstract

“…Lung cancer is the most common cause of cancer death worldwide [1]. Among all lung cancer cases, approximately 85% in Korea and 80% worldwide were confirmed to be non-small-cell lung cancer (NSCLC) [2]. These patients face a poor prognosis and low 5-year survival rate despite development of novel treatments [3,4].…”

Section: Introductionmentioning

confidence: 99%

CDCP1 Expression Is a Potential Biomarker of Poor Prognosis in Resected Stage I Non-Small-Cell Lung Cancer

Nam

Choi

Park

et al. 2022

JCM

Self Cite

View full text Add to dashboard Cite

Background: Although early-stage lung cancer has increased owing to the introduction of screening programs, high recurrence rate remains a critical concern. We aimed to explore biomarkers related to the prognosis of surgically resected non-small-cell lung cancer (NSCLC). Methods: In this retrospective study, we collected medical records of patients with NSCLC and matched tissue microarray blocks from surgical specimens. Semiquantitative immunohistochemistry was performed for measuring the expression level of fibroblast activation protein-alpha (FAP-α), Jagged-1 (JAG1), and CUB-domain-containing protein 1 (CDCP1). Results: A total of 453 patients who underwent complete resection between January 2011 and February 2012 were enrolled; 55.2% patients had stage I NSCLC, and 31.1% presented squamous cell carcinoma. Disease stage was a significant risk factor for recurrence and death, and age ≥ 65 years and male sex were associated with poor overall survival. FAP-a and JaG1 were not related to survivals, while CDCP1-expressing patients exhibited poor disease-free and overall survival. Moreover, CDCP1 expression in stage I NSCLC was significantly associated with recurrence. Conclusions: Old age, male sex, and high pathological stage were poor prognostic factors in patients with NSCLC who underwent surgical resection. Furthermore, CDCP1 expression could serve as a biomarker for poor prognosis in stage I NSCLC.

show abstract

Recent Trends of Lung Cancer in Korea

Cited by 43 publications

References 29 publications

Prognosis and recurrence patterns in patients with early stage lung cancer: a multi-state model approach

Prognosis and recurrence patterns in patients with early stage lung cancer: a multi-state model approach

Impact of COPD treatment on survival in patients with advanced non-small cell lung cancer

CDCP1 Expression Is a Potential Biomarker of Poor Prognosis in Resected Stage I Non-Small-Cell Lung Cancer

Contact Info

Product

Resources

About